Latest:
Dr. Abdallah on Interim Efficacy Data on HPN217 in R/R Multiple Myeloma
Al-Ola A. Abdallah, MD, discusses interim results from an ongoing phase 1 trial of HPN217 in heavily pretreated patients with relapsed/refractory multiple myeloma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Maryam Lustberg, MD, MPH
Latest:
Breaking Down the Data in Genitourinary, Gastrointestinal, and Breast Cancers, Plus Sarcoma and Melanoma at ASCO 2023: Drs Rini, Lewis, Trent, Luke, Kunz, and Lustberg
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.
Paula Rodriguez-Otero, MD
Paula Rodriguez-Otero, MD is a consultant oncologist and deputy professor at the University of Navarra.
Latest:
Dr Rodriguez-Otero on Data for Linvoseltamab in High-Risk Smoldering Myeloma
Paula Rodriguez-Otero, MD, discusses safety and efficacy findings with linvoseltamab, a bispecific antibody targeting BCMA, in patients with high-risk smoldering multiple myeloma.
Matthew Rettig, MD
Latest:
Dr. Rettig on the Evolving Use of Triplet Regimens in mHSPC
Matthew Rettig, MD, discusses the evolution of triplet therapy within the landscape of metastatic hormone-sensitive prostate cancer, as well as the importance of considering key prognostic factors when utilizing this approach.
Anthony M Hunter, MD
Anthony M. Hunter, MD, is an assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta, Georgia.
Latest:
Dr Hunter on the Role of Momelotinib as First-Line Therapy in Myelofibrosis
Anthony M. Hunter, MD, discusses the role of momelotinib for the treatment of adult patients with myelofibrosis and moderate to severe anemia.
Carla van Herpen, MD, PhD
Latest:
Petosemtamab (MCLA-158) With Pembrolizumab as First-Line (1L) Treatment of PD-L1+ Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Phase 2 Trial
Carla van Herpen, MD, PhD, presents phase 2 trial results showing that petosemtamab plus pembrolizumab in first-line PD-L1–positive recurrent/metastatic HNSCC achieved a 63% response rate, 9-month median PFS, and 79% 1-year OS, with durable responses and a favorable safety profile.
Eric Christenson, MD
Eric Christenson, MD, is an assistant professor of oncology at the Johns Hopkins School of Medicine
Latest:
Oncodetect MRD Test Aids Treatment Decision-Making in CRC and Other Solid Tumors: With Eric Christenson, MD
Dr Christenson discusses the capabilities of the Oncodetect test, its clinical applications and pronostic value, and findings from the Alpha-CORRECT study.
Michael R. Cook, MD
Latest:
Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCL
Michael R. Cook, MD, discusses real-world data associated with the utilization of bridging therapy prior to treatment with axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma.
Hedyeh Ebrahimi, MD, MPH
Hedyeh Ebrahimi, MD, MPH, is a postdoctoral fellow at City of Hope Comprehensive Cancer Center.
Latest:
Dr Ebrahimi on Clinical Outcomes With the Addition of CBM588 to Cabozantinib and Nivolumab in RCC
Hedyeh Ebrahimi, MD, MPH, discusses clinical outcomes with CBM588 plus cabozantinib and nivolumab in metastatic renal cell carcinoma.
Samantha Fisch, MD
Samantha Fisch, MD is a second-year internal medicine resident at the University of California San Francisco.
Latest:
Dr Fisch on the Incidence of Neutropenia With Sacituzumab Govitecan in Advanced Breast Cancer
Samantha Fisch, MD, discusses rates of neutropenia in patients with advanced breast cancer treated with sacituzumab govitecan.
University of Florida Health
Latest:
UF Health Cancer Center Achieves National Cancer Institute Designation
The University of Florida Health Cancer Center has received prestigious designation from the National Cancer Institute, or NCI, and joins the ranks of the country’s most distinguished cancer centers, becoming the 72nd in the United States and the only one in North Central Florida.
Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center
Latest:
Advanced Biliary Tract Cancers: Managing Immunotherapy-Related Adverse Events
Expert perspectives on the toxicity profile of immunotherapy agents and how they can be managed in patients being treated for advanced biliary tract cancers.
Jacob Soumerai, MD
Latest:
Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow Up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)
Dr. Jacob Soumerai provides a comprehensive 5-year follow-up on the multicenter Phase II trial of the BOVen regimen (zanubrutinib, obinutuzumab, and venetoclax) in treatment-naïve chronic lymphocytic leukemia, highlighting sustained undetectable minimal residual disease rates, retreatment outcomes, and the prognostic significance of MRD kinetics (ΔMRD400).